Recombinant Human IFN-alpha-1a Protein, CF

Catalog #: 11014-IF Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
11014-IF-010
11014-IF-050

Recombinant Human IFN-alpha-1a Protein Bioactivity.

2 Images

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human IFN-alpha-1a Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129. The ED₅₀for this effect is 0.100-1.50 ng/mL.

Source

Human embryonic kidney cell, HEK293-derived human IFN-alpha 1 protein
Cys24-Glu189

Accession #

P01562.1

N-terminal Sequence
Analysis

Cys24

Predicted Molecular Mass

19 kDa

SDS-PAGE

17-21 kDa, under reducing conditions.

Product Datasheets

11014-IF

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

11014-IF

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 100 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity

View Larger

Recombinant Human IFN alpha-1a Protein (Catalog # 11014-IF) demonstrates anti-viral activity in HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. The ED₅₀ for this effect is 0.100-1.50 ng/mL

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human IFN-alpha-1a Protein (Catalog # 11014-IF) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 17‑21 kDa.

Reconstitution Calculator

Background: IFN-alpha 1

Interferons (IFN) are a family of cytokines with potent anti‑viral, antiproliferative and immunomodulatory properties, classified based on their binding specificity to cell surface receptors (1). Human IFNA2 was originally cloned in the early ‘80s and now more than a dozen closely related IFN alpha subtypes have been identified in both the human and mouse genome, each sharing about 80% amino acid (aa) sequence homology (2-4). Structurally, type I IFNs belong to the class of five helical‑bundle cytokines, with the IFNA subtypes containing 2 conserved disulfide bonds (5). Mature human IFNA1, also known as IFNA13, shares 63% amino acid (aa) sequence identity with mouse IFNA1. Two variants of human IFNA1 are known to exist, IFNA1a and IFNA1b, which only differ by a single aa at residue 137 (6). The type I IFNs bind to the interferon alpha receptor (IFNAR), which consists of two subunits: IFNAR1 (alpha -subunit) and IFNAR2 (beta -subunit) (7, 8). IFNA1 is the most expressed IFNA subtype and primarily expressed by plasmacytoid dendritic cells (pDC), which are the earliest cells recruited to the sites of virus entry (9). Individual IFNA subtypes are known to display unique efficacies to viral protection, and IFNA1 exhibits low potency, determined by both anti‑viral and antiproliferative activities (10). Human IFNA1 was the first IFNA to be purified and has been tested as a treatment for various diseases (11-13).

References